Edition:
United Kingdom

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

9.40EUR
3:55pm BST
Change (% chg)

€-0.08 (-0.84%)
Prev Close
€9.48
Open
€9.57
Day's High
€9.60
Day's Low
€9.24
Volume
47,471
Avg. Vol
61,473
52-wk High
€18.12
52-wk Low
€7.91

Latest Key Developments (Source: Significant Developments)

Nanobiotix Q2 Revenue Drops To 31,900 Euros
Friday, 19 Jul 2019 

July 19 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX ANNOUNCES SECOND QUARTER 2019 REVENUE.COMPANY'S CASH AVAILABILITY AS OF JUNE 30, 2019 AMOUNTED TO EUR 54.9M.Q2 REVENUE EUR 31.9 K VERSUS EUR 73,3 K YEAR AGO.COMPANY’S CASH VISIBILITY NOW EXTENDS THROUGH THE END OF 2020..  Full Article

Nanobiotix Announces New Organizational Structure
Monday, 1 Jul 2019 

July 1 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX ANNOUNCES NEW ORGANIZATIONAL STRUCTURE AS THE COMPANY ENTERS ITS NEXT STAGE AFTER FIRST EUROPEAN MARKET APPROVAL.RECENTLY APPOINTED CHIEF MEDICAL OFFICER (CMO) EDWINA BASKIN-BEY, M.D., WILL JOIN EXECUTIVE BOARD.ANNE-JULIETTE HERMANT, M.A., WILL BE APPOINTED CHIEF PEOPLE OFFICER (CPO) AND WILL JOIN EXECUTIVE BOARD.CHIEF BUSINESS OFFICER (CBO) BERND MUEHLENWEG, PH.D., WILL STEP DOWN FROM EXECUTIVE BOARD AND EXIT COMPANY.PATRICK TRICOLI, PHARM.D. M.B.A., WILL REMAIN CEO OF NANOBIOTIX CORP, COMPANY'S U.S. AFFILIATE, AND ALSO TAKE ON A NEW ROLE AS GLOBAL HEAD OF BUSINESS DEVELOPMENT.  Full Article

Nanobiotix Appoints Edwina Baskin-Bey As New Chief Medical Officer
Tuesday, 4 Jun 2019 

June 4 (Reuters) - Nanobiotix SA ::NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL.BIOPHARMACEUTICAL VETERAN EDWINA BASKIN-BEY, M.D., JOINS NANOBIOTIX AS ITS NEW CHIEF MEDICAL OFFICER.DR. BASKIN-BEY WILL LEVERAGE HER EXPERTISE IN MEDICAL STRATEGY AND LATE-STAGE CLINICAL DEVELOPMENT TO HELP ACCELERATE COMPANY'S STRATEGIC OBJECTIVES.DR. BASKIN-BEY SUCCEEDS ELSA BORGHI, M.D., WHO WILL REMAIN FOCUSED ON EARLY DEVELOPMENT OF INNOVATIVE PRODUCTS AT NANOBIOTIX.  Full Article

Nanobiotix Announces Results Of Combination NBTXR3, Radiotherapy, And Anti-PD-1 Immunotherapy
Tuesday, 2 Apr 2019 

April 2 (Reuters) - NANOBIOTIX SA ::COMBINATION OF FIRST-IN-CLASS NBTXR3, RADIOTHERAPY, AND ANTI-PD-1 IMMUNOTHERAPY DEMONSTRATE EFFICACY IN TREATING RESISTANT PRE-CLINICAL IN VIVO MODELS OF LUNG CANCER.IN VIVO STUDY DEMONSTRATED NBTXR3 IN COMBINATION WITH PD-1 INHIBITOR ENHANCED ABSCOPAL EFFECT IN BOTH SENSITIVE AND PD-1-INHIBITOR-RESISTANT LUNG CANCER MODELS.IT ALSO DEMONSTRATED NBTXR3 IN COMBINATION WITH PD-1 INHIBITOR SHOWED SIGNIFICANT REDUCTION OF METASTATIC LOAD IN PD-1-INHIBITOR- SENSITIVE LUNG CANCER MODELS.IT ALSO DEMONSTRATED THAT NBTXR3 IN COMBINATION WITH CTLA-4 INHIBITOR ENHANCED AN ABSCOPAL EFFECT IN COLORECTAL CANCER MODELS.  Full Article

Nanobiotix FY Net Loss Grows To 30.3 Million Euros
Friday, 15 Mar 2019 

March 15 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX 2018 ANNUAL RESULTS.CONSOLIDATED CASH AVAILABLE OF €36.2M AT DECEMBER 31, 2018.FY NET LOSS EUR 30.3 MILLION VERSUS LOSS OF EUR 26.1 MILLION YEAR AGO.FY OPERATING LOSS EUR 30.1 MILLION VERSUS LOSS OF EUR 25.3 MILLION YEAR AGO.THIS YEAR NANOBIOTIX EXPECTS TO RECEIVE ITS CE MARK FOR NBTXR3 FOR THE TREATMENT OF SOFT TISSUE SARCOMA,.TOTAL REVENUE IN 2018 AMOUNTED TO €3.5M VERSUS. €3.7M IN 2017.  Full Article

Nanobiotix And MD Anderson Cancer Center Announce Clinical Collaboration On NBTXR3
Monday, 7 Jan 2019 

Jan 7 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX AND MD ANDERSON CANCER CENTER ANNOUNCE A LARGE-SCALE, COMPREHENSIVE CLINICAL COLLABORATION ON NBTXR3.COLLABORATION INCLUDES A $12M TOTAL INVESTMENT FROM NANOBIOTIX.MOST OF TRIALS ARE EXPECTED TO BE LAUNCHED IN 2019.COLLABORATION WILL INITIALLY SUPPORT NINE NEW PHASE I/II CLINICAL TRIALS WITH NANOBIOTIX'S FIRST-IN-CLASS AGENT NBTXR3.PART OF PAYMENT WILL BE MADE AT START OF COLLABORATION.OTHER PARTS WILL BE PAID DURING DEVELOPMENT AND BALANCE IN CASE OF FDA REGISTRATION FOR A TOTAL OF $12M INVESTMENT.  Full Article

Nanobiotix: Positive Phase II/III Results For NBTXR3 In Soft Tissue Sarcoma
Friday, 19 Oct 2018 

Oct 19 (Reuters) - NANOBIOTIX SA ::NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO.NBTXR3 IS FIRST RADIOTHERAPY ENHANCER TO DEMONSTRATE CLINICALLY MEANINGFUL BENEFIT FOR PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA COMPARED TO RADIOTHERAPY ALONE.NBTXR3 IS FIRST RADIOTHERAPY ENHANCER TO DEMONSTRATE CLINICALLY MEANINGFUL BENEFIT FOR PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA COMPARED TO RADIOTHERAPY ALONE.PRIMARY AND MAIN SECONDARY ENDPOINTS WERE MET.IN SUBGROUP OF PATIENTS HAVING AN ADVANCED DISEASE, 4-TIMES MORE PATIENTS ACHIEVED A PATHOLOGICAL COMPLETE RESPONSE IN NBTXR3 ARM COMPARED TO CONTROL ARM.NBTXR3 SHOWED A GOOD LOCAL TOLERANCE AND NO IMPACT ON SEVERITY OR INCIDENCE OF RADIOTHERAPY-RELATED ADVERSE EVENTS.  Full Article

Nanobiotix H1 Operating Loss 13.0 Million Euros
Tuesday, 4 Sep 2018 

Sept 4 (Reuters) - NANOBIOTIX SA ::H1 TOTAL REVENUE EUR 2.1 MILLION VERSUS EUR 1.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR 13.0 MILLION VERSUS LOSS OF EUR 11.8 MILLION YEAR AGO.H1 LOSS EUR 12.6 MILLION VERSUS LOSS OF EUR 12.2 MILLION YEAR AGO.SAYS CASH POSITION AT THE END OF JUNE ENABLES US TO SECURE OUR GROWTH BEYOND 2019.GROUP HAD CASH AND CASH EQUIVALENTS AT JUNE 30, 2018 OF €32.7 M (31 DECEMBER 2017: €47.2M).  Full Article

Nanobiotix Q2 2018 Revenue EUR 73K, Fully In Line With Its Expectations
Thursday, 12 Jul 2018 

July 12 (Reuters) - Nanobiotix SA ::COMPANY GENERATED €73K DURING THE SECOND QUARTER OF 2018, WHICH IS FULLY IN LINE WITH THE COMPANY’S EXPECTATIONS..CURRENTLY, THE COMPANY IS EVALUATING NBTXR3 IN SEVEN CLINICAL TRIALS WITH A FOCUS ON HEAD AND NECK CANCERS AND IMMUNO-ONCOLOGY PROGRAMS.Q2 REVENUE EUR 73,304 VERSUS EUR 58,499 YEAR AGO.  Full Article

Nanobiotix Did Not Generate Any Revenue In Q1
Wednesday, 16 May 2018 

May 16 (Reuters) - NANOBIOTIX SA ::ANNOUNCED ON TUESDAY IT DID NOT GENERATE ANY REVENUE FOR Q1 2018, AS IT HAD EXPECTED.  Full Article

French and Benelux stocks-Factors to watch on April 5

April 5 Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.